Jason Coloma Sells 11,411 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 11,411 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $296,800.11. Following the transaction, the chief executive officer owned 27,362 shares of the company’s stock, valued at approximately $711,685.62. This trade represents a 29.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Maze Therapeutics Stock Up 1.3%

MAZE traded up $0.34 during trading on Friday, hitting $26.21. The stock had a trading volume of 273,266 shares, compared to its average volume of 637,671. The company has a market capitalization of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. Maze Therapeutics, Inc. has a twelve month low of $14.27 and a twelve month high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock has a 50 day simple moving average of $28.74 and a two-hundred day simple moving average of $31.20.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). On average, research analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Analyst Ratings Changes

MAZE has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $66.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics in the fourth quarter worth about $43,000. California State Teachers Retirement System grew its holdings in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after acquiring an additional 766 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics during the second quarter worth about $48,000. Finally, Ameritas Investment Partners Inc. raised its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.